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SUMMARY
Purpose: One-year clinical experience with pulse dose rate (PDR) brachytherapy is presented.
Material and methods: Between March 1999 and June 2000 intracavitary, intraluminal, and interstitial
PDR brachytherapy was pertormed in 119 patients with a variety of malignancies. The dose per pulse
ot 0.5-4 Gy, repeated each hour, or 6 Gy per application was administered, up to the totał dose
of 6-70 Gy, using a microSelectron-PDR remote afterloading system with a 1921r source of 1 Ci nominal
activity. The planning system PLATO BPS (version 13) was used tor dose calculations. Depending
on individual applications, the algorithms ot the dose point, the geometrical volume, or the geometrical
point dose distribution optimization in POR treatment planning were pertormed. In 40 patients therapy
was given with a curative intent, and 74 cases were treated palliatively. In the remaining five patients
PDR was applied as salvage therapy in the previously irradiated area.
Results: With a median tollow-up ot 11 months (range 1-18 months) local control was maintained until
the last follow-up or death in 39 out of 40 patients treated with radical intent. The subjective
improvement was achieved in more than a half of patients with advanced esophageal and lung
carcinomas presenting dysphagia and dyspnoe. Signiticant acute toxicity (severe esophagitis
precluding subsequent PDR application) occurred in only one patient. Delayed vaginal cuff necrosis
was observed in one woman who received prior pelvic irradiation for gynaecological cancer.
Conclusion: The POR brachytherapy is a safe and clinically effective method in a variety of malignan-
cies. The possibility ot programme optimization combined with the use ot relatively wide range ot pulse
doses makes it possible to deliver an optimal brachytherapy scheme.
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INTRODUCTION
Recent technical and radiobiological
developments have led to the impro-
vement of brachytherapy methods.
This progress is particularly due to the de-
velopment of modern afterloading equip-
ment and miniaturisition of 1921r stepping
sources for afterloading machines.
Moreover, advances in the threedimen-
tional (3D) treatment planning software
incorporated computerized tomography
information which helped to define target
and critical volumes in conformal bra-
chytherapy. Another advantage was im-
proved radiation protection of the staff
and visitors.
Modern brachytherapy uses remote
afterloading devices with a single cable-
driven radioactive source, moved through
a series ot positions within an implanted
volume, or a set of intracavitary instru-
ments. The source stops for a specified
period of time, at a selected number
of locations during its transit, and delivers
a cumulative dose to the entire volume.
In pulsed dose rate (PDR) brachytherapy
this cumulative dose consists of a series
ot smali doses (pulses) delivered at a gi-
ven frequency over a period ot hours
or days.
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POR remote afterloading systems arose
as a compromise between low dose rate
(LOR) and high dose rate (HOR) remote
afterloading systems. This method offers
several advantages. Radiobiologically
it resembles LDR brachytherapy but
at the same time, it helps to optimize
isodose distributions. The latter aim
is achieved by manipulating the location
and number of source-stopping ("dwell")
positions, as well as by various periods
the source spends at each dwell position
within the implanted array.
The nominal activity of a single 1921r
source is 1 Ci or less, which enables
a POR remote afterloading system
to be installed in existing or only modified
shielded rooms suitable for LOR bra-
chytherapy. Radiobiologic data suggest
that POR therapy and traditional
continuous LOR therapy, if delivered with
the same total dose and dose rate,
produce similar biological effects for both
acute- and late-reacting tissues [1, 4, 7].
According to these theoretical calculations
and in vitro studies, the recommended
dose rate should be lower than 1 Gy
(typically 0.5 - 0.6 Gy/hr), the pulse
duration should be 10 minutes or more
(or a dose rate not exceeding 3 Gy/hr
during a pulse), and the pulses should
be repeated every hour [3, 9, 10].
PDR brachytherapy was initiated
at the Oepartment of Oncology and Radio-
therapy, Medical University of Gdańsk,
in March 1999. We have been using
Table 1. Tumor site distribution and PDR treatment characteristics.
a microSelectron-POR remote afterloading
machine with a 1921r stepping source enclo-
sed in a capsule 1.1 mm in diameter
and 2.5 mm long, and of 1 Ci activity
at installation.
Here we report on our own early
experience with this technique.
MATERIALS AND METHOOS
Between March 16, 1999 and June 30,
2000 intracavitary, intraluminal and inter-
stitial POR brachytherapy was performed
in atotal of 119 patients (Table 1).
PDR treatments were prescribed
as an exclusive modality or in combination
with external beam therapy (EBRT).
In 40 patients, POR was given with
a curative intent, and 74 cases were
treated palliatively. In the remaining 5 pa-
tients, POR was applied as a salvage
therapy in the previously irradiated area.
POR procedures were performed using
one pulse per hour with the dose per pulse
of 0.5-3 Gy in cases treated with definitive
irradiation and re-irradiated, and 1-4 Gy
per pulse in cases treated palliatively.
Another method used atotal dose of 6 Gy
in one prolonged pulse. The pulse duration
was 5-90 minutes, depending on the vo-
lume of the implant or insertion, prescribed
dose, and the source activity at the time
of the procedure. Source-dwell interval
in the applicator was usually 2.5 mm,
whereas 5 mm interval was used only
occasionally.
Site Indication/intent Number Oose/pulse Target dose
ofcases (Gy) (Gy)
Esophagus Palliative 31 1 12-40
Lung Palliative/Radical 20 3,6 6-27
Breast Boost after EBRT 20 1 10-20
Gynecological Radical/Postoperative 13 1-6 6-50
Palliative 5 0.6-6 12-45
Head and neck Radical 8 0.6-1 15-70
Miscellaneous Palliative/Postoperative 15 0.5-1 9-30
Computer-assisted treatment planning
was performed based on orthogonal
radiographs, with the applicator(s)
in place. The planning system PLATO
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BPS (version 13) was used to obtain
satisfactory dose distributions. The tre-
atment plan was optimized for each
application based on the algorithm
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of the dose point, the geometrical volume,
or the geometrical point dose distribution.
The Paris system rules for interstitial
implants were used. The clinical target
volume was determined with at least 1 cm
safety margins around the gross tumour
volume, as detected by clinical findings
and additional imaging data.
Intra-operatively placed interstitial
implants using plastic catheters were used
in three cases of abdominal/pelvic cancer.
In these situations, the POR procedure
started one to two days after the catheter
implantation. A CT-guided stereotactic
navigation system was used for interstitial
implants in five cases of intracranial tu-
mours. The breast implant templates were
placed under both local or general anae-
sthesia. Ali patients were carefully super-
vised by a dedicated nurse during the en-
tire time of application.
Treatment toxicity was scored with
the use of an RTOG/EORTC scale.
Lung and esophageal cancer
Ali but one of the 20 patients with lung
cancer and 31 patients with esophageal
cancer were treated palliatively to control
troublesome symptoms, in particular dys-
phagia and dyspnoe. Fifteen patients with
lung cancer and ten patients with eso-
phageal cancer received external beam
radiotherapy (EBRT), usually hypofractio-
nated. The laser therapy prior to POR was
applied in 12 cases of esophageal carcino-
ma. In most cases, two weekly (range 1-3)
intraluminal applications were used.
Standard treatment programmers were
employed for a single intraluminal ca-
theter. This policy enabled the POR
treatment take started imme-diately after
the installation of the appli-cator and after
checking the radiographs. The dose was
normalized to the dose point at 1O mm
distance from the center of the active part
of the applicator.
One patient with intraepithelial bronchial
carcinoma received three POR intra-
luminal placements with a dose of 9 Gy
each (3Gy/pulse/h), as a part of planned
definitive radiotherapy. This patient refu-
sed further treatmenł.
Breast cancer
Breast cancer POR interstitial breast
implantations with doses of 10-20 Gy
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(1 Gy/pulse/hr) as a boost to EBRT with
the dose of 50-60 Gy, were applied in four
patients with locally advanced breast
cancer, and in 16 patients with early
breast cancer as a part of breast-
conserving therapy. Typically, double-
piane interstitial breast implants with both
flexible er rigid tubes were made. Oose
calculation and specification folIowed
the rules of the Paris system, in which rigid
tubes are used. In cases with flexible
tubes, volume optimized dose distributions
was applied.
Gynaecological malignancies
POR brachytherapy was applied in 18 pa-
tients including seven patients, with cer-
vical cancer, and 11 with endometrial
cancer. The POR technique, instead
of LOR caesium applications routinely
used by us in gynaecological malignan-
cies, was employed in cases with medical
contraindications to prolonged immo-
bilization and in patients who refused LOR
brachytherapy due to the longer treatment
time. POR was also applied in all patients
reirradiated to the pelvis, with increased
risk of radiation-induced morbidity.
In 11 cases POR was a part of definitive
radiotherapy; two endometrial cancer
cases received postoperative vaginal cuff
irradiation, and the remaining five patients
were irradiated for vaginal recurrence
of endometrial or cervical cancer. Four
cases of the latter group received prior
radical irradiation to the pelvis. The care-
fully prescribed total doses of 6-50 Gy
(median 25 Gy), and the dose per pulse
of 0.6, 1.0, 2.0 or 2.5 Gy, were typically
used. In four cases, in order to shorten
the overall treatment time, a dose
ot 4 or 6 Gy per pulse was administered.
Atotal of 10 applications using Simon
catheters (four to nine in each insertion)
at a dose of 7.5 Gy or 10 Gy were made
in four endometrial cancer patients, either
applied alone or combined with EBRT.
The Simon catheter applications were
used weekly or twice a week.
Head and neck cancer
POR implants were made in five patients
with lip carcinoma and in two patients with
buccal carcinoma. Two or three flexible
catheters were used, and 1 Gy/pulse
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to 60-70 Gy total dose was given.
The POR boost ot 15 Gy (0.6 Gy/pulse)
was administered in one patient with
a residual tumour atter 60 Gy EBRT
squamous carcinoma ot the hard palate.
The mould was constructed to accommo-
date three tlexible tubes.
Re-irradiation
A total ot tive POR procedures ot 30-35 Gy
(0.6 Gy/pulse) were performed in pre-
viously irradiated sites. These included
four gynaecological vaginal applications
and one intra-operatively placed pelvic
implant in a patient with rectal cancer.
Prior detinitive radiotherapy in this group
included EBRT and intracavitary brachy-
therapy in three, and EBRT alone in two
cases. Earlier therapy was performed
2, 4, and 18 years earlier.
Miscellaneous tumours
These included cranial tumours, both pri-
mary and metastastic, urethral cancer,
prostate cancer, bile duct cancer, rectal
cancer, and malignant melanoma.
Oifferent techniques of application and di-
fferent doses were used in this group
ot patients.
RESULTS
At the time ot this analysis (January 2001),
all breast cancer patients were alive, with
no evidence ot disease tor a median
ot 11 months (range ot 6 to 15 months).
Postirradiation skin changes in the boost
area (minimum teleangiectasia at puncture
sites) appeared in only one patienł. Six
ot the eight head and neck cancer patients
were alive with no evidence ot disease
at 9 to 17 months tollow-up. One patient
developed nodal recurrence without local
recurrence 3 months after the POR
treatmenł. This patient is alive without
evidence ot disease after 60 Gy EBRT
to the region ot disease recurrence. Local
disease progression was observed in one
patient 6 months after combined EBRT
and POR therapy tor hard palate cancer.
Eleven ot the 18 gynaecological cancer
patients remained tree ot disease
tor a period ot 6-13 months, three patients
died ot disease progression 7, 10,
and 15 months after treatment, respe-
ctively, two patients died due to inter-
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current disease, and one was lost to in the
tollow-up. No local recurrence during the
tollow-up ot 7 and 11 months was
observed in three out ot tive re-irradiated
patients. The remaining two patients died
due to a progressive pelvic disease.
The palliative ettect was achieved in 61 %
and 50% ot cases with esophageal and
lung cancer, respectively. This ettect
lasted for 1 to 8 months. The subsequent
POR application for symptomatic recur-
rence was given in three patients (one
lung cancer and two esoghageal cancers).
The second application was made 6, 9
and 11 months atter the first POR
treatmenł. No evidence ot cancer
tor a period ot 8 months was observed
in a patient treated tor the intraepithelial
bronchial carcinoma.
In most instances, POR brachytherapy
was well tolerated and in all but one case
there were no severe acute reactions. One
patient developed esophageal mucositis
(grade 4 RTOG/EORTC scale) precluding
subsequent POR application. Mild con-
tluent mucositis and moderate desqua-
mation were seen in patients treated tor lip
and buccal carcinomas. This damage
resolved atter 2-3 weeks. In one patient
previously irradiated to the pelvic region
with a dose ot 60 Gy the vaginal cutt
necrosis occurred atter the POR treatment
and has persisted tor 11 months.
Oisplacement ot the intraluminal tube
occured in two patients with esophageal
carcinoma. Additionally, there were rela-
tively trequent minor problems and break-
downs during POR treatmenł. The most
common problem was related to the great
curvature ot plastic tubes which did not
make it possible to load check cable.
Because ot major tailures we had to seek
occasionally the manufacturers advice.
DISCUSSION
Oue to the smali number ot cases
in cohorts and the short tollow-up, this
study has tocused on acute reactions,
technical teasibility and patient tolerance
ot POR brachytherapy. No severe acute
toxicity was observed in all but one patient
who had POR intracavitary, intraluminal
and interstitial brachytherapy administered
with radical and palliative intenł.
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The possibility of disconnecting the patient
from the machine during the "quiescent"
period is of great importance for patient's
comfort.
The first pulsed LOR Selectron from
Nucietron Corporation was installed
at the University of California, San Fra-
ncisco in early 1992. Since then several
studies have been reported on POR
brachytherapy in many cancer sites
including pelvis, head and neck,
and breast [9, 11, 13, 14, 15, 16]. These
studies confirmed that POR may replace
traditional continuous LOR brachytherapy.
No significant increase in toxicity above
that seen with the standard continuous
LOR approach, and excellent local control
in patients treated with POR have been
reported, although the need for a longer
follow-up required for fuli assessment
of this modality has been recognized
[13,16]. This technique is expected
to be at least as clinically efficacious
(in terms of both tumor control and late
sequelae) as the continuous LOR regimen
[6].
As the damage to late reacting tissues
is closely related to the brachytherapy
dose rate, the POR technique should
be taken into consideration in all patients
who had been re-irradiated [5, 12].
To minimize the risk of complications
the dose rate of 0.4 - 0.6 Gy per pulse
is preferable in such patients.
The POR system makes it possible
to change the dose rate from a pulsed low
dose rate to a continuous medium/high
dose rate. As our institution is equipped
with only one additional LOR/MOR unit
for gynaecological applications, POR
treatment was also performed
in an attempt to minimize the duration
of the treatment time. Short immobilization
is particularly useful in elderly and frail
gynaecological patients. Moreover,
the POR system provides the delivery
of a relatively high dose in a short time
in cases treated with palliative intent.
The relatively high source activity
requires the assistance of additional staff,
and this economic aspect should be taken
into the account. Oaytime- only schedules
(Le. "extended office hours" - 8 a.m.
to 8 p.m., with no irradiation overnight)
are therefore considered [2].
To achieve equivalence between
the LOR and POR irradiation regimens,
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the total dose using both techniques
should be administered with the same
overall time [1, 8]. This involves the need
for prolonged installation of applicators
and, in consequence, - extended patient
immobilization. The intermittent nature
of the radiation leads, however, to greater
patients comfort, and closer contacts with
his ar her family and the staff.
A common technical problem
accompanying POR applications is kinking
or flattening of the tubes inside or outside
the patient (including the connection
between the catheter and the transfer
tube). We have also experienced several
situations when the incorrect transfer
of the check cable occurred, which
resulted in a delay in the treatment onset
or subsequent breakdowns. To alleviate
this problem, semi-rigid catheters have
been introduced. Another technical
problem accompanying POR therapy
involves large curvature of plastic tubes
precluding transfer of the source. This pro-
blem may appear in cases treated with
a loop technique, commonly used in head
and neck cancer patients.
CONCLUSIONS
The POR brachytherapy has been
shown to offer a reliable, safe and
c1inically effective method for both radical
and palliative management. This proce-
dure is suitable in almost ali tumor
localizations. The optimization of treatment
planning programs combined with
the possibility of using a relatively wide
range of doses delivered per pulse help
to obtain adaptation of brachytherapy
to specific needs. No major problems are
encountered while using a micro-Selectron
POR unit. For the evaluation of c1inical
results a longer follow-up is needed.
REFERENCES
1. Brenner DJ, Hall EJ. Conditions
tor the equivalence ot continuous to pulsed
low dose rate brachytherapy. Int J Radiat
Oncol Biol Phys 1991 ;20:181-90.
2. Brenner DJ, Schiff PB, Huang Y, Hall EJ.
Pulsed-dose-rate brachytherapy: design
ot convenient (daytime-only) schedules. Int J
Radiat Oncol Biol Phys 1997;39:809-15.
139
Serkies et al.: POR brachytherapy: a report •..
3. Chen CZ, Huang Y, Hall EJ, Brenner DJ.
Pulsed brachytherapy as a substitute
tor continuous low dose rate: an in vitro
study with human carcinoma cells.
Int J Radiat Oncol Biol Phys 1997;37:
137-43.
4. Hall EJ, Brenner DJ. The dose-rate effect
revisited; radiobiological considerations
ot importance in radiotherapy. Int J Radiat
Oncol Biol Phys 1991 ;21 :1403-14.
5. Hall EJ, Brenner DJ. The dose-rate effect
in interstitial brachytherapy: A controversy
resolved. Br J Radiol 1992;65:242-7.
6. van Eilkeren M, Thienpont M, Boterberg T,
de Neve W. Implementation, uptime,
and satety ot pulsed dose rate afterloading
machine. Int J Radiat Oncol Biol Phys
1996;36:1233-7.
7. Fowler J, Mount M. Pulsed brachytherapy:
the conditions tor no signiticant loss
ot therapeutic ratio compared with
traditional low dose rate brachytherapy.
Int J Radiat Oncol Biol Phys 1992;23:
661-9.
8. Fowler JF, van Limbergen EF. Biological
effect ot pulsed dose rate brachytherapy
with stepping sources it short half-times
ot repair are present in tissues. Int J Radiat
Oncol Biol Phys 1997;37:877-83.
9. Fritz P, Berns C, Anton HW, Hensley F,
Assman J, Flentje M, et al. PDR brachy-
therapy with tlexible implants tor interstitial
boost after breast-conserving surgery
and external beam radiation therapy.
Radiat Oncol 1997;45:23-32.
10. Keilholz L, Seegenschmiedt MH, Lotter M,
Schulz-Wendtland R, von Erfta J,
Ptluger S, et al. Effects ot tractionation
and dose rate in PDR brachytherapy.
Strahlentherapie und Onkologie 1998;174:
64-70.
140
11. Levenndag PC, Schmitz PI, Jansen PP,
Senan S, Eijkenboom WM, Sipkema D,
et al. Fractionated high-dose-rate
and pulsed-dose-rate brachyhterapy: tirst
clinical experience in squamous celi
carcinoma of the tonsillar fossa and soft
palate. Int J Radiat Oncol Biol Phys
1997;38:497-506.
12. Mason KA, Thames HD, Ochran TG,
Ruifrok AC, Janjan N. Comparison
ot continuous and pulsed low dose rate
brachytherapy: Biological equivalence
in vivo. Int J Radiat Oncol Biol Phys
1994;28:667-71.
13. de Pree C, Popowski Y, Weber D, Nouet
P, Rouzaud M, Kurtz JM. Feasibility
and tolerance ot pulsed dose rate
interstitial brachytherapy. Int J Radiat
Oncol Biol Phys 1999;43:971-6.
14. Roed H, Engelholm SA, Svendsen LB,
Rosendal F, Olsen KJ. Pulsed dose rate
(PDR) brachytherapy ot anal carcinoma.
Radiat Oncol 1997;44:296-7.
15. Strnad V, Lotter M, Grabenbauer G, Sauer
R. Early results ot pulsed-dose-rate
interstitial brachytherapy for head and
neck malignancies after limited surgery.
Int J Radiat Oncol Biol Phys 2000;46:27-30.
16. Swift PS, Purser P, Roberts LW, Pickett B,
Powell CB, Phillips T. Pulsed law dose rate
brachytherapy for pelvic malignancies.
Int J Radiat Oncol Biol Phys 1997;37:811-7.
Rep. Pract. Oncol. Radiother. 6 (3) 2001
